By Alfonso Serrano — 2017
MDMA-assisted psychotherapy readies for phase III trials, a last step before possible prescription use in PTSD patients.
Read on www.scientificamerican.com
CLEAR ALL
The last time I was on ketamine, I was hooked up to an IV following surgery. This time, the drug—in general medical use as an anesthetic since 1970—arrived on my doorstep courtesy of Mindbloom, a new telemedicine company specializing in ketamine-based psychedelic therapy.
1
A new review of studies finds that LSD, psilocybin, and MDMA hold potential for treating mental illness.
Now, as a handful of patients and more recently doctors and therapists have been granted exemptions to use psilocybin, the nation’s federal health agency is considering making changes to existing policies that could open the door to much more than magic mushrooms.
My first psilocybin journey began around an altar in the middle of a second-story loft in a suburb of a small city on the Eastern Seaboard.
2
A new generation of research into psilocybin could change how we treat numerous mental health conditions.
Study participants at some of the country's leading medical research centers are going through intense therapy and six-hour psychedelic journeys deep into their minds to do things like quit smoking and worry less.